Neutec Group
http://www.neutec.com.tr/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Neutec Group
Turkey's Abdi Ibrahim Beats Multinationals On Domestic Pharma Market
The Turkish pharmaceutical market reached $5.6bn in 2017. Despite strong competition from multinationals, Abdi Ibrahim, a local company, was market leader last year with a turnover of $380m. It was followed by Novartis and Pfizer.
Takeda’s Planned Emerging Markets Deal: India Yay Or Nay?
Takeda tantalizingly disclosed during its third quarter results that it has set aside funds for an acquisition worth around $450m in an undisclosed emerging market. What are the likely targets?
Turkey Company Roundup: Biosimilar Pact, Keytruda Supply, Takeda Deal
TUBITAK (The Scientific and Technological Research Council of Turkey
) will produce biosimilars with Nobel Ilac, MSD provides pembrolizumab free to 25 patients in Turkey, Abdi Ibrahim intensifies its R&D efforts, and Takeda purchases a portfolio of new products.
Deals Shaping The Medical Industry, March 2015
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February 2015.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- Other Names / Subsidiaries
-
- Takeda Pharmaceutical Company Limited
- Neutec Ilac Sanayi Ve Ticaret AS
- Neutec Inhale
- Neutec Cef
- Neutec Solid
- Neutec R&D
- Neutec Ilaç Sanayi ve Ticaret A.S.
- Neutec Pharma Group
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice